- All
- Event Participitation (7)
- News & Press releases (8)
- Scientific Publication (4)
Scientific Publication
Cycuria’s Scientific Founder Co-Authors A Commemorative Review Article on „Cell Death in Cancer“
Prof Philipp Jost, along with other leading experts in the field, authored an invited commemorative review in Cell by Cell Press — titled “𝘾𝙚𝙡𝙡 𝘿𝙚𝙖𝙩𝙝...
Event Participitation
Cycuria to Present at the AACR Annual Meeting 2026 in San Diego
We are excited to share that our Founder, 𝗣𝗿𝗼𝗳. 𝗗𝗿. Philipp Jost, will be presenting at the 𝗔𝗔𝗖𝗥 𝗔𝗻𝗻𝘂𝗮𝗹 𝗠𝗲𝗲𝘁𝗶𝗻𝗴 𝟮𝟬𝟮𝟲 in San Diego this...
News & Press releases
📢 Cycuria’s Scientific Vision Featured in Drug Target Review article
We’re proud to share that 𝗣𝗿𝗼𝗳. 𝗗𝗿. Philipp Jost , Scientific Founder of Cycuria Therapeutics , is featured in Drug Target Review discussing innovative strategies...
News & Press releases
Cycuria Therapeutics Featured on the Base-to-Base Biotech Podcast!
Our CEO & Co-Founder, Nisit Khandelwal, joined host Jim Cornall on the 𝗕𝗮𝘀𝗲-𝘁𝗼-𝗕𝗮𝘀𝗲 𝗕𝗶𝗼𝘁𝗲𝗰𝗵 𝗣𝗼𝗱𝗰𝗮𝘀𝘁 to discuss Cycuria Therapeutics’ approach to treating some of the...
Scientific Publication
Lymphotoxin alpha eradicates acute myeloid leukemia and simultaneously promotes healthy hematopoiesis in mice
Editor’s summary Relapse of acute myeloid leukemia (AML) is driven by populations of leukemic stem or progenitor cells (LSCs), which are resistant to chemotherapy. Here,...
News & Press releases
Cycuria Publishes Groundbreaking Research in Science Translational Medicine Demonstrating Lymphotoxin Alpha Eradicates Acute Myeloid Leukemia
The study, led by Cycuria’s scientific founder, Prof. Dr. Philipp Jost , a clinician-scientist, and his research team, describes a natural tumor-suppressing mechanism mediated by...